# US 2016/0235722 A1 · Stable Solid Immunosuppressor Composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235722 A1
- Document ID: US20160235722A1
- Status: Published application
- Kind: A1
- Application number: 14/909,261
- Filed: 2014-07-24
- Published: 2016-08-18
- Earliest claimed: 2013-08-02
- Assignees: Laboratorio Raam De Sahuayo, S.A. De C.V.
- Applicants: Laboratorio Raam De Sahuayo, S.A. De C.V.
- Inventors: Federico Amezcua Amezcua
- Web page: https://patentgrep.com/patent/US20160235722A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 31/42: Oxazoles
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein is a stable solid pharmaceutical composition including 1) one or more immunosuppressant agents and/or pharmaceutically acceptable salts thereof; 2) a stabilizing mixture including i) vitamin E oil, ii) L-leucine, and iii) one or more poloxamers; and, 3) one or more pharmaceutically acceptable excipients, contained in at least one dosage unit.

## Claims

### Claim 1

A stable solid pharmaceutical composition comprising: 1) one or more immunosuppressant agents and/or pharmaceutically acceptable salts thereof; 2) a stabilizing mixture comprising i) vitamin E oil, ii) L-leucine, and iii) one or more poloxamers; and, 3) one or more pharmaceutically acceptable excipients, contained in at least one dosage unit.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition comprises from 0.01 to 20 percent of one or more immunosuppressant agents and/or pharmaceutically acceptable salts thereof, and/or polymorphs and/or prodrugs by total weight of the composition.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the immunosuppressive agent is selected from the group consisting of glucocorticoids, leflunomide, sirolimus, cyclophosphamide, antimalarials, methotrexate, etanercept, infliximab, adalimumab, anakinra, rituximab; pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the immunosuppressant agent is sirolimus, and/or its pharmaceutically acceptable salts and/or polymorphs, and/or prodrugs thereof.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the stabilizing mixture contains from 0.1 to 10 percent of vitamin E oil by total weight of the composition; from 0.1 to 10 percent of L-leucine by total weight of the composition, and 0.1 to 15.0 percent of one or more poloxamers by total weight of the composition.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition contains from 20 to 99.9 percent by total weight of the composition of one or more pharmaceutically acceptable excipients selected from the group consisting of: microcrystalline cellulose, magnesium stearate, crospovidone, purified water, polyvinylpyrrolidone, povidone, ethanol, lactose, hydroxypropyl methylcellulose, polyethylene glycol, propylene glycol, polypropylene glycol, stearic acid, starch, and pregelatinized starch.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the dosage unit is a tablet, coated tablet, controlled-release tablet, granules, soft gelatin capsule, hard gelatin capsule, pellets, and/or micro tablets.

### Claim 8

(canceled)

### Claim 9

A method of preventing or treating organ transplant rejection comprising administering to an organism in need thereof a composition comprising a stable solid pharmaceutical composition comprising: 1) one or more immunosuppressant agents and/or pharmaceutically acceptable salts thereof; 2) a stabilizing mixture comprising i) vitamin E oil, ii) L-leucine, and iii) one or more poloxamers; and, 3) one or more pharmaceutically acceptable excipients, contained in at least one dosage unit.
